|
 The Pharmaceuticals Export Promotion Council of India (Pharmexcil) has reported that India's pharmaceutical export continued its growth trajectory with USD 2,475.70 million in May 2025, cumulating to USD 4,961.71 million for April-May FY26.
“This growth is a testament to Pharmexcil’s efforts in spearheading a transformative period for India's pharmaceutical sector, moving beyond its 'Pharmacy of the World' reputation to embrace cutting-edge sustainable manufacturing, expand its global market presence, and streamline regulatory processes through digital innovation. With the Department of Commerce setting a trillion-dollar trade target for the pharmaceutical sector, Pharmexcil is poised to provide deeper insights and strategic direction to the industry, driving leadership in innovation, affordability, and excellence to meet this ambitious goal," said Namit Joshi, chairman of Pharmexcil.
Pharmexcil's commitment to global collaboration is evident through various engagements across countries. iPHEX 2025, scheduled from 4 to 6 September 2025 under Bharat Health, is also set to serve as a global platform to showcase India's pharmaceutical capabilities, fostering innovation and international partnerships. India's pharmaceutical exports continue to demonstrate a steady year-over-year growth, with drug formulations and biologicals continuing to dominate the export category, Joshi explained
He further added, “We attribute this growth to rising global demand, streamlined regulatory approvals, technological innovations, strategic partnerships, and economic stability. As a nodal agency, we also strive to enhance buyer-seller communications in order to increase the ease of doing business globally. Pharmexcil continues to simplify essential processes through digital services, ensuring efficiency for industry stakeholders."
Formulations and biologicals continue to hold the major share of India’s total exports accounting for 75.74% during this period. The second major category by value is bulk drugs and drug intermediates. During May 2025-26 this segment expanded by 4.40%.
Vaccines were the third largest exported category, valued at USD 190.13 million, experiencing a significant 13.64% increase. Surgicals grew by 8.58%, reaching USD 124.62 million. Ayush & Herbals products saw a 7.36% growth, with a value of USD 119.89 million.
NAFTA, Europe, Africa and LAC are Pharmexcil’s four major regions for pharma exports. These four regions together account for 76% of total pharma exports. ASEAN (4.88%) was a newly contracted region during this period.
India’s top 5 countries for pharma exports during May 2025-26 were USA, UK, Brazil, South Africa, and France.
Exports to USA, which account for 34.50% of exports in pharma products, have expanded by 1.50%. Pharma exports to the USA were valued at USD 1711.75 million during May 2025-26. Europe grew moderately by 3.14%, and Africa by 1.71%.
Joshi also lauds the progress on India-UK Free Trade Agreement (FTA) discussions, which is expected to enhance supply chains, improve access to affordable medicines, and foster foreign direct investment (FDI), particularly in contract development and manufacturing (CDMO) and joint research.
“Pharmexcil continues its robust efforts to expand India's pharmaceutical presence worldwide. And the India-UK Free Trade Agreement (FTA) marks a milestone in economic cooperation, particularly in the field of pharmaceuticals enhancing supply chains and access to affordable medicines by encouraging collaborations," Joshi said.
Pharmexcil is organising iPHEX 2025, a premier exhibition that brings together the drugs, pharmaceutical and healthcare industries under one roof, offering a comprehensive platform for networking, business development, and knowledge sharing. The exhibition also plays a pivotal role in fostering international trade, with over 600+ overseas buyers from key focus areas being invited to engage with Indian manufacturers, suppliers, and service providers.
|